REG - PureTech Health PLC - Transaction in Own Shares
23/10/2023 07:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231023:nRSW8751Qa&default-theme=true
RNS Number : 8751Q PureTech Health PLC 23 October 2023
23 October 2023
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.
Date of purchase: 20 October 2023
Number of ordinary shares purchased: 30,962
Highest price paid per share: 168.80p
Lowest price paid per share: 162.60p
Volume weighted average price paid per share: 166.20p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have 15,673,503 ordinary
shares in treasury and has 273,794,656 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 273,794,656 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/) or connect with us on X, formerly known as
Twitter, @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number
20/10/2023 08:07:43 130 162.6 AQXE 00374738779TRLO0.1.1
20/10/2023 10:15:14 168 164.2 BATE 00374767645TRLO0.1.1
20/10/2023 10:17:50 33 164.2 AQXE 00374768553TRLO0.1.1
20/10/2023 10:21:29 310 164.2 XLON 00374769350TRLO0.1.1
20/10/2023 10:21:29 98 164.2 XLON 00374769351TRLO0.1.1
20/10/2023 10:21:35 522 164.2 XLON 00374769413TRLO0.1.1
20/10/2023 10:21:35 598 164.2 XLON 00374769414TRLO0.1.1
20/10/2023 10:21:43 56 164.2 AQXE 00374769491TRLO0.1.1
20/10/2023 10:21:43 142 164.2 BATE 00374769492TRLO0.1.1
20/10/2023 10:21:43 310 164.2 CHIX 00374769493TRLO0.1.1
20/10/2023 10:21:43 214 164.2 BATE 00374769494TRLO0.1.1
20/10/2023 10:21:43 105 164.2 AQXE 00374769495TRLO0.1.1
20/10/2023 10:21:51 280 164.6 XLON 00374769518TRLO0.1.1
20/10/2023 10:21:51 73 164.6 XLON 00374769520TRLO0.1.1
20/10/2023 10:21:51 62 164.6 XLON 00374769519TRLO0.1.1
20/10/2023 10:30:15 61 164 XLON 00374771518TRLO0.1.1
20/10/2023 10:30:36 194 164 AQXE 00374771575TRLO0.1.1
20/10/2023 10:30:36 806 164 XLON 00374771576TRLO0.1.1
20/10/2023 10:31:18 373 164 XLON 00374771750TRLO0.1.1
20/10/2023 10:31:19 406 164 XLON 00374771754TRLO0.1.1
20/10/2023 10:31:19 151 164 XLON 00374771753TRLO0.1.1
20/10/2023 10:53:59 502 166.4 XLON 00374776322TRLO0.1.1
20/10/2023 10:53:59 98 166.6 XLON 00374776323TRLO0.1.1
20/10/2023 10:57:00 307 166.6 XLON 00374777292TRLO0.1.1
20/10/2023 11:30:38 43 168.2 XLON 00374784296TRLO0.1.1
20/10/2023 11:30:38 85 168.2 XLON 00374784297TRLO0.1.1
20/10/2023 11:30:38 12 168.2 XLON 00374784298TRLO0.1.1
20/10/2023 11:31:11 311 168.2 XLON 00374784409TRLO0.1.1
20/10/2023 11:31:21 295 168.4 XLON 00374784437TRLO0.1.1
20/10/2023 11:31:21 61 168.4 XLON 00374784438TRLO0.1.1
20/10/2023 11:31:21 200 168.4 XLON 00374784439TRLO0.1.1
20/10/2023 11:39:49 310 168.8 CHIX 00374786564TRLO0.1.1
20/10/2023 11:39:56 930 167.8 XLON 00374786580TRLO0.1.1
20/10/2023 11:43:25 96 167.2 TRQX 00374787822TRLO0.1.1
20/10/2023 11:43:25 81 167.2 TRQX 00374787821TRLO0.1.1
20/10/2023 11:43:25 15 167.2 TRQX 00374787823TRLO0.1.1
20/10/2023 11:43:25 95 167.2 CHIX 00374787825TRLO0.1.1
20/10/2023 11:43:25 215 167.2 CHIX 00374787824TRLO0.1.1
20/10/2023 11:43:25 930 167.4 XLON 00374787826TRLO0.1.1
20/10/2023 11:43:25 100 167.2 CHIX 00374787828TRLO0.1.1
20/10/2023 11:43:25 210 167.2 CHIX 00374787827TRLO0.1.1
20/10/2023 11:43:25 143 166.8 BATE 00374787829TRLO0.1.1
20/10/2023 11:43:25 3 166.8 BATE 00374787831TRLO0.1.1
20/10/2023 11:43:25 4 166.8 BATE 00374787830TRLO0.1.1
20/10/2023 11:43:25 54 166.8 BATE 00374787832TRLO0.1.1
20/10/2023 12:19:36 68 168 XLON 00374794666TRLO0.1.1
20/10/2023 12:19:36 69 168 XLON 00374794667TRLO0.1.1
20/10/2023 12:24:31 194 168.2 AQXE 00374795760TRLO0.1.1
20/10/2023 12:31:46 175 167.2 BATE 00374797020TRLO0.1.1
20/10/2023 12:31:46 496 168 XLON 00374797021TRLO0.1.1
20/10/2023 12:31:46 7 167.2 TRQX 00374797022TRLO0.1.1
20/10/2023 12:31:46 310 167.2 CHIX 00374797023TRLO0.1.1
20/10/2023 12:31:46 96 167.2 TRQX 00374797025TRLO0.1.1
20/10/2023 12:31:46 190 167.2 CHIX 00374797024TRLO0.1.1
20/10/2023 12:31:46 89 167.2 TRQX 00374797026TRLO0.1.1
20/10/2023 12:31:46 54 167.2 BATE 00374797028TRLO0.1.1
20/10/2023 12:31:46 81 167.2 BATE 00374797027TRLO0.1.1
20/10/2023 12:31:46 310 167.2 BATE 00374797029TRLO0.1.1
20/10/2023 12:31:46 103 168 XLON 00374797030TRLO0.1.1
20/10/2023 12:31:46 194 167.4 AQXE 00374797031TRLO0.1.1
20/10/2023 12:31:46 403 168 XLON 00374797032TRLO0.1.1
20/10/2023 12:31:46 19 167.4 XLON 00374797033TRLO0.1.1
20/10/2023 12:31:46 3800 167.4 XLON 00374797034TRLO0.1.1
20/10/2023 12:38:09 238 166.4 XLON 00374798319TRLO0.1.1
20/10/2023 12:53:10 14 165.2 XLON 00374801096TRLO0.1.1
20/10/2023 12:53:10 74 165.2 XLON 00374801095TRLO0.1.1
20/10/2023 13:18:19 350 165.8 XLON 00374805821TRLO0.1.1
20/10/2023 13:18:19 45 165.8 XLON 00374805822TRLO0.1.1
20/10/2023 13:18:19 15 165.8 XLON 00374805823TRLO0.1.1
20/10/2023 13:18:19 91 165.8 XLON 00374805824TRLO0.1.1
20/10/2023 13:47:38 287 165.2 BATE 00374811970TRLO0.1.1
20/10/2023 13:47:38 96 165.2 TRQX 00374811971TRLO0.1.1
20/10/2023 13:47:38 195 165.2 BATE 00374811972TRLO0.1.1
20/10/2023 13:47:38 800 165.2 XLON 00374811973TRLO0.1.1
20/10/2023 13:47:38 440 165.2 XLON 00374811974TRLO0.1.1
20/10/2023 13:47:38 194 165.2 AQXE 00374811975TRLO0.1.1
20/10/2023 14:30:01 194 166.6 AQXE 00374823479TRLO0.1.1
20/10/2023 14:30:05 430 166.4 CHIX 00374823671TRLO0.1.1
20/10/2023 14:32:55 310 166.2 CHIX 00374825293TRLO0.1.1
20/10/2023 14:34:26 324 165.8 XLON 00374825853TRLO0.1.1
20/10/2023 15:04:17 310 166 BATE 00374836483TRLO0.1.1
20/10/2023 15:04:17 310 166 BATE 00374836484TRLO0.1.1
20/10/2023 15:04:17 1240 166 XLON 00374836485TRLO0.1.1
20/10/2023 15:04:23 110 166 AQXE 00374836500TRLO0.1.1
20/10/2023 15:06:20 84 166 AQXE 00374837293TRLO0.1.1
20/10/2023 15:06:20 31 165.8 CHIX 00374837295TRLO0.1.1
20/10/2023 15:06:20 126 166 AQXE 00374837294TRLO0.1.1
20/10/2023 15:06:20 13 165.8 CHIX 00374837297TRLO0.1.1
20/10/2023 15:06:20 96 165.8 TRQX 00374837296TRLO0.1.1
20/10/2023 15:09:05 298 165.8 CHIX 00374838392TRLO0.1.1
20/10/2023 15:09:05 266 165.8 CHIX 00374838391TRLO0.1.1
20/10/2023 15:09:05 1240 165.6 XLON 00374838393TRLO0.1.1
20/10/2023 15:26:28 611 165.8 XLON 00374845340TRLO0.1.1
20/10/2023 15:32:01 23 165.6 XLON 00374847907TRLO0.1.1
20/10/2023 15:32:01 310 165.6 XLON 00374847906TRLO0.1.1
20/10/2023 15:39:31 96 166 TRQX 00374851365TRLO0.1.1
20/10/2023 15:39:42 3 166 BATE 00374851413TRLO0.1.1
20/10/2023 16:02:11 242 166 CHIX 00374871099TRLO0.1.1
20/10/2023 16:07:36 516 166.2 XLON 00374873407TRLO0.1.1
20/10/2023 16:07:36 279 166.2 XLON 00374873408TRLO0.1.1
20/10/2023 16:07:36 50 166.2 XLON 00374873409TRLO0.1.1
20/10/2023 16:07:36 275 166.2 CHIX 00374873412TRLO0.1.1
20/10/2023 16:07:36 194 166.2 AQXE 00374873411TRLO0.1.1
20/10/2023 16:07:36 160 166.2 XLON 00374873414TRLO0.1.1
20/10/2023 16:07:36 35 166.2 CHIX 00374873413TRLO0.1.1
20/10/2023 16:07:36 545 166.2 XLON 00374873415TRLO0.1.1
20/10/2023 16:10:40 82 166 BATE 00374874880TRLO0.1.1
20/10/2023 16:10:40 50 166 BATE 00374874881TRLO0.1.1
20/10/2023 16:10:40 15 166 BATE 00374874884TRLO0.1.1
20/10/2023 16:10:40 1550 166 XLON 00374874882TRLO0.1.1
20/10/2023 16:10:40 163 166 BATE 00374874883TRLO0.1.1
20/10/2023 16:21:46 390 166.2 CHIX 00374881460TRLO0.1.1
20/10/2023 16:22:44 192 166.2 CHIX 00374882090TRLO0.1.1
20/10/2023 16:23:47 110 166 AQXE 00374882613TRLO0.1.1
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSFLFFDIVLIFIVRecent news on Puretech Health
See all newsREG - PureTech Health PLC - Total Voting Rights
AnnouncementREG - PureTech Health PLC - Final Results
AnnouncementREG - PureTech Health PLC - Notice of Results
AnnouncementRCS - PureTech Health PLC - PRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
AnnouncementRCS - PureTech Health PLC - FDA Grants PRTC's LYT-200 Fast Track Designation
Announcement